CA-GILEAD-SCIENCES
9.9.2019 13:32:14 CEST | Business Wire | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation today announced the launch of the ground-breaking RADIAN initiative at the Fast-Track Cities 2019 conference in London. RADIAN seeks to meaningfully address new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia (EECA). RADIAN builds on the existing collaboration between the Foundation and Gilead in the EECA Key Populations (EECAKP) fund, leveraging both organizations’ greater understanding of the region’s needs to drive forward bold and meaningful action to address specific challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190909005498/en/
“Every day, more than 400 people in EECA become infected with HIV and 100 die from AIDS,” said Sir Elton John, Founder, Elton John AIDS Foundation. “My Foundation’s work in establishing the Eastern Europe and Central Asia Key Populations (EECAKP) fund with Gilead and others a couple of years ago forcefully underscored for us the need to drastically expand our efforts in the region. So, I’m delighted that the Foundation is once again working with Gilead through RADIAN to provide much-needed support and funding to reverse trends and reach some of the world’s most vulnerable people. Together, we can create change, save lives and ensure no one is left behind in the fight to end the epidemic.”
Addressing the epidemic in EECA is imperative to the global effort to eliminate HIV/AIDS. According to UNAIDS, while rates of new HIV infections and deaths from AIDS-related illnesses are now decreasing globally, EECA is one of the few regions where HIV is on the rise and deaths from AIDS have increased by approximately 300 percent in the last 20 years.
“Gilead and the Foundation share a vision to end the HIV epidemic. Through RADIAN, we aim to reach marginalized populations in the EECA region and work with local organizations to address some of the challenges they face,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “RADIAN will help to provide the funding and support for the HIV response that have historically been lacking in the region. There are more than one million people living with HIV in EECA who need access to appropriate care. This needs to be urgently addressed through education, community empowerment and novel partnerships such as this.”
The RADIAN initiative is comprised of two key elements, the RADIAN “Model Cities” program and the RADIAN “Unmet Need” fund. By adapting a dual-track program, RADIAN can direct resources to communities in need that are immediately ready to scale interventions through targeted funding, while simultaneously building capacity in others. HIV has high prevalence in communities that often face stigma and have limited access to care. By partnering with local organizations, RADIAN will leverage on-the-ground insights and share the best practices that are needed to make meaningful progress.
The first RADIAN Model City will be Almaty, Kazakhstan. Almaty faces a disproportionately heavy burden of HIV. There are approximately 7,400 people living with HIV in Almaty, and the city has an HIV prevalence that is almost twice the national average. RADIAN will support Almaty in achieving improved HIV outcomes by addressing stigma, strengthening healthcare infrastructure and care models and increasing access to innovation. Additional Model Cities will be announced in 2020.
“We are happy that Kazakhstan will be part of the RADIAN initiative,” said Dr. Bauyrzhan Baiserkin, Director of the Kazakh Scientific Center of Dermatology and Infectious Diseases, based in Almaty. “We have ambitions to reach those that live with or are at risk of HIV to ensure as many of them as possible can get tested and treated so they can live healthy lives. We welcome this support and commitment from the RADIAN initiative to help Kazakhstan continue our progress and ultimately achieve our targets.”
In order to support the rest of the EECA region beyond the selected Model Cities, RADIAN will also implement the Unmet Need fund, to support impactful initiatives in other parts of EECA. Grants will be available for local and regional organizations in EECA who share RADIAN’s vision to address new HIV infections and deaths from AIDS-related illnesses. The Request for Proposals will open in mid-October 2019.
Across both elements, RADIAN aims to contribute measurable changes in HIV incidence, linkage to care and treatment coverage and prevention, to meaningfully address new HIV infections and AIDS-related deaths in EECA. Best practices and learnings from the local implementation of RADIAN over the next five years will be used as a blueprint toward helping change the trajectory of HIV across the region.
About RADIAN
RADIAN is a ground-breaking initiative between the Elton John AIDS Foundation and Gilead Sciences. It aims to meaningfully address new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia (EECA), where deaths from AIDS have increased by around 300 percent in the last 20 years.
The Elton John AIDS Foundation and Gilead have an established presence in EECA and extensive experience working effectively with key stakeholders. Through a focused investment of up to $25 million, as well as provision of resources on the ground, RADIAN is a natural evolution of this initiative, leveraging a deep understanding of the EECA community to drive forward the shared ambition to end the HIV epidemic.
Both organizations, as well as potential additional partners in the future, will work together to ensure no one is left behind in the global effort to eliminate HIV/AIDS. Join us in addressing new HIV infections and deaths from AIDS-related illnesses in EECA: www.radianHIV.org .
About the Elton John AIDS Foundation
The Elton John AIDS Foundation is one of the foremost independent AIDS charities in the world. At the Foundation, we believe AIDS can be beaten. We act on that belief by raising funds for evidence-based frontline programs and policies and speaking out with honesty and compassion about the realities of people’s lives. Sir Elton John created the Foundation in 1992. Since then, through hard work and with the help of our network of kind and generous friends and supporters, the Foundation has raised more than $450 million globally to combat stigma, prevent infections, provide treatment and services, and motivate governments to end AIDS. Join us in speaking out, taking action, and continuing the fight against this worldwide pandemic so that no one is left behind.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it is estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
For more information, please visit www.ejaf.org , follow the Foundation on Twitter (@ejaf), Facebook @eltonjohnaidsfoundation and Instagram (@ejaf).
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190909005498/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom